If MRSA bacteria enter the skin, an infection can develop. Such infections do not go away on their own and require immediate treatment to prevent complications. Methicillin-resistant ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
However, the bacteria can sometimes enter a break in the skin, causing a serious infection that requires immediate treatment. In the early stages, an MRSA infection may cause a raised bump on the ...
The gold standard antimicrobial, vancomycin, has several shortcomings that have prompted the development of newer agents for the treatment of MRSA disease ... from common skin infections such ...
Exebacase is under clinical development by Aurobac Therapeutics and currently in Phase I for Prosthetic Joint infections.
Hospital acquired (HA)-MRSA and community acquired ... in the initiation and progression of infections via direct tissue damage to mucosal membranes and skin. Protein-synthesis inhibition is ...
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs ...
Medically reviewed by Susan Bard, MD Having psoriasis, an autoimmune condition that causes inflamed skin patches, can make ...
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial ...
"The licensing of Zevtera expands IST’s diverse yet complementary portfolio of differentiated treatments that address substantial ... approved cephalosporin specifically for MRSA ...
Public health officials are concerned that we could move back into a situation like that of the early 20th century, before ...
Zevtera is indicated for the treatment of adult patients with SAB, including right-sided infective endocarditis, and adult patients with acute bacterial skin and skin structure infections (ABSSSI ...